These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 4007612)

  • 1. Action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) against untreated human ovarian cancers in the murine xenograft assay.
    Micha JP; Kucera PR; Preve CU; Rettenmaier MA; Stratton JA; DiSaia PJ
    Gynecol Oncol; 1985 Jul; 21(3):351-5. PubMed ID: 4007612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin.
    Finlay GJ; Ching LM; Wilson WR; Baguley BC
    J Natl Cancer Inst; 1987 Aug; 79(2):291-6. PubMed ID: 3474463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases.
    Robins RK; Srivastava PC; Narayanan VL; Plowman J; Paull KD
    J Med Chem; 1982 Feb; 25(2):107-8. PubMed ID: 7057413
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Maroun JA; Stewart DJ
    Invest New Drugs; 1990; 8 Suppl 1():S33-9. PubMed ID: 2380015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro studies of Tiazofurin and a selenazole analog.
    Streeter DG; Robins RK
    Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of nucleosides and nucleotides related to the antitumor agent 2-beta-D-ribofuranosylthiazole-4-carboxamide.
    Srivastava PC; Revankar GR; Robins RK
    J Med Chem; 1984 Mar; 27(3):266-9. PubMed ID: 6699872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
    Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
    Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice.
    Lapis K; Pápay J; Paku S
    Oncology; 1990; 47(4):359-64. PubMed ID: 2367062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of 2-beta-d-Ribofuranosylthiazole-4-carboxamide (tiazofurin) in Chinese hamster ovary and variant cell lines.
    Saunders PP; Kuttan R; Lai MM; Robins RK
    Mol Pharmacol; 1983 Mar; 23(2):534-9. PubMed ID: 6188036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
    Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
    Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiazofurin: biological effects and clinical uses.
    Tricot G; Jayaram HN; Weber G; Hoffman R
    Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
    Melink TJ; Sarosy G; Hanauske AR; Phillips JL; Bayne JH; Grever MR; Jayaram HN; Von Hoff DD
    Sel Cancer Ther; 1990; 6(1):51-61. PubMed ID: 2343202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
    Harrison SD; O'Dwyer PJ; Trader MW
    Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
    Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
    Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
    Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.